MA53015A - Anticorps anti-sirp-bêta1 et procédés d'utilisation associés - Google Patents

Anticorps anti-sirp-bêta1 et procédés d'utilisation associés

Info

Publication number
MA53015A
MA53015A MA053015A MA53015A MA53015A MA 53015 A MA53015 A MA 53015A MA 053015 A MA053015 A MA 053015A MA 53015 A MA53015 A MA 53015A MA 53015 A MA53015 A MA 53015A
Authority
MA
Morocco
Prior art keywords
sirp
associated procedures
beta1
antibodies
beta1 antibodies
Prior art date
Application number
MA053015A
Other languages
English (en)
Inventor
Patricia Culp
Andrew Pincetic
Arnon Rosenthal
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Publication of MA53015A publication Critical patent/MA53015A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
MA053015A 2018-06-29 2019-06-28 Anticorps anti-sirp-bêta1 et procédés d'utilisation associés MA53015A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862691913P 2018-06-29 2018-06-29

Publications (1)

Publication Number Publication Date
MA53015A true MA53015A (fr) 2021-05-05

Family

ID=67439371

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053015A MA53015A (fr) 2018-06-29 2019-06-28 Anticorps anti-sirp-bêta1 et procédés d'utilisation associés

Country Status (14)

Country Link
US (2) US12060422B2 (fr)
EP (1) EP3814377A2 (fr)
JP (2) JP7575278B2 (fr)
KR (1) KR20210025614A (fr)
CN (2) CN119912569A (fr)
AU (1) AU2019293589A1 (fr)
BR (1) BR112020026819A2 (fr)
CA (1) CA3099176A1 (fr)
EA (1) EA202190138A1 (fr)
IL (1) IL279648A (fr)
MA (1) MA53015A (fr)
MX (1) MX2020013324A (fr)
SG (1) SG11202010990TA (fr)
WO (1) WO2020006374A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3317297A4 (fr) 2015-06-30 2019-03-20 Sanford-Burnham Medical Research Institute Protéine de fusion agonistes de btla et leurs utilisations
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
BR112022021450A2 (pt) * 2020-04-24 2022-12-27 Millennium Pharm Inc O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada
CN116253797B (zh) * 2020-05-19 2024-05-14 益科思特(北京)医药科技发展有限公司 抗新型冠状病毒Spike蛋白抗体及其应用
WO2022115350A1 (fr) * 2020-11-30 2022-06-02 Merck Sharp & Dohme Corp. Liants d'arginase 1 pour inhiber l'activité de l'arginase 1
EP4623930A3 (fr) * 2020-12-03 2026-02-25 The Board Of Regents Of The University Of Texas System Procédés d'identification d'anticorps bloquant lilrb
CA3231484A1 (fr) 2021-10-01 2023-04-06 Qinwen Mao Tdp-43 pathologique utilise en tant que biomarqueur pour le diagnostic de la proteinopathie tdp-43
CN114478802B (zh) * 2022-01-28 2023-05-26 郑州大学 一种嵌合抗原受体及其应用
EP4619435A1 (fr) 2022-11-16 2025-09-24 Boehringer Ingelheim International GmbH Biomarqueurs d'efficacité prédictive pour anticorps anti-sirpa
EP4676953A2 (fr) * 2023-03-09 2026-01-14 Triveni Bio, Inc. Anticorps de kallicréine à double inhibiteur et leurs utilisations
WO2025049347A1 (fr) * 2023-08-25 2025-03-06 Triveni Bio, Inc. Anticorps ciblant klk5/7 + il-4 et leurs utilisations
IL326559A (en) * 2023-08-25 2026-04-01 Triveni Bio Inc Antibodies targeting KLK5/7 + IL-13 and their uses
IL326558A (en) * 2023-08-25 2026-04-01 Triveni Bio Inc KLK5/7 + TH2-targeted antibodies and their uses
WO2025101471A1 (fr) * 2023-11-09 2025-05-15 Merck Sharp & Dohme Llc Dosage de puissance biologique à base de cellules d'anticorps anti-cd27
WO2025166138A1 (fr) * 2024-02-02 2025-08-07 Triveni Bio, Inc. Anticorps ciblant klk5/7 + tslp et leurs utilisations
WO2025166146A1 (fr) * 2024-02-02 2025-08-07 Triveni Bio, Inc. Anticorps ciblant klk5/7 + ox40 et leurs utilisations

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (fr) 1991-09-19 2003-11-11 Paul J. Carter Expression dans e. coli de fragments d'anticorps ayant au moins une cysteine presente sous forme de thiol libre. utilisation pour la production d'anticorps f(ab') bifonctionnels
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
WO1993016185A2 (fr) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Proteine de liaison biosynthetique pour marqueur de cancer
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1997011971A1 (fr) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Proteines d'interaction de cellules porcines
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
WO2001040307A1 (fr) 1999-11-30 2001-06-07 Eberhard-Karls-Universität Tübingen Universitätsklinikum Anticorps diriges contre les proteines regulatrices de signal
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
CA2481837A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Procede de production de composition anticorps
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
CA2561686C (fr) 2004-03-31 2014-12-02 Genentech, Inc. Anticorps anti-tgf-beta humanises
JP4224586B2 (ja) * 2004-04-28 2009-02-18 国立大学法人群馬大学 マクロファージ活性化剤並びにその製造方法及びスクリーニング方法
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
ES2965283T3 (es) 2006-03-15 2024-05-28 Alexion Pharma Inc Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento
CA2651567A1 (fr) 2006-05-09 2007-11-22 Genentech, Inc. Polypeptides de liaison a squelettes optimises
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (fr) 2007-09-14 2020-04-15 Adimab, LLC Bibliothèques d'anticorps synthétiques conçus de façon rationnelle et leurs utilisations
EP3663318A1 (fr) 2008-01-07 2020-06-10 Amgen Inc. Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
CN101880324B (zh) 2010-05-25 2012-10-17 中国人民解放军第二军医大学 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
EP3321286B1 (fr) 2011-08-23 2021-01-06 Roche Glycart AG Molécules bispécifiques de liaison à l'antigène activant des lymphocytes t
US20140242095A1 (en) 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
AU2013267161A1 (en) * 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
WO2014179363A1 (fr) 2013-04-29 2014-11-06 Adimab, Llc Réactifs multispécificité, procédés de préparation et d'utilisation associés
WO2015138600A2 (fr) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anticorps anti-sirp-alpha et anticorps bispécifiques de stimulation des macrophages
GB201413357D0 (en) * 2014-07-28 2014-09-10 Philogen Spa Antibodies for treatment and diagnosis
AU2016219772A1 (en) * 2015-02-22 2017-09-21 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
EP3341411B1 (fr) 2015-08-28 2025-06-11 Alector LLC Anticorps anti-siglec-7 et leurs méthodes d'utilisation
JP7628764B2 (ja) * 2015-09-29 2025-02-12 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
WO2018210795A1 (fr) * 2017-05-16 2018-11-22 Synthon Biopharmaceuticals B.V. ANTICORPS ANTI-SIRPα

Also Published As

Publication number Publication date
JP7575278B2 (ja) 2024-10-29
CA3099176A1 (fr) 2020-01-02
AU2019293589A1 (en) 2021-01-21
CN112384532B (zh) 2025-01-10
SG11202010990TA (en) 2020-12-30
US20250026827A1 (en) 2025-01-23
IL279648A (en) 2021-03-01
BR112020026819A2 (pt) 2021-04-20
US20210277113A1 (en) 2021-09-09
EP3814377A2 (fr) 2021-05-05
WO2020006374A3 (fr) 2020-02-20
CN119912569A (zh) 2025-05-02
EA202190138A1 (ru) 2021-05-27
JP2024119792A (ja) 2024-09-03
KR20210025614A (ko) 2021-03-09
JP2021529520A (ja) 2021-11-04
CN112384532A (zh) 2021-02-19
MX2020013324A (es) 2021-05-12
WO2020006374A2 (fr) 2020-01-02
US12060422B2 (en) 2024-08-13

Similar Documents

Publication Publication Date Title
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
EP3797123A4 (fr) Anticorps anti-ox40 et procédés d'utilisation
MA50956A (fr) Anticorps anti-cd137 et procédés d'utilisation correspondants
MA52781A (fr) Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
EP3824096A4 (fr) Nouveaux anticorps et leurs procédés de préparation et d'utilisation
EP3950716A4 (fr) Anticorps anti-claudine 18.2 et utilisation associée
MA50359A (fr) Anticorps anti-cd38 et procédés d'utilisation
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
EP3684821A4 (fr) Anticorps anti-hla-a2 et leurs procédés d'utilisation
MA43365A (fr) Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
EP3472200A4 (fr) Anticorps anti-myostatine et leurs procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA52416A (fr) Anticorps b7-h4 et leurs procédés d'utilisation
EP3710589A4 (fr) Anticorps anti-c1s et procédés d'utilisation
EP3731867A4 (fr) Anticorps anti-lrp5/6 et leurs procédés d'utilisation
EP3436476A4 (fr) Anticorps anti-ryk et leurs procédés d'utilisation
EP3645049A4 (fr) Anticorps multispécifiques et procédés de préparation et d'utilisation associés
MA50516A (fr) Anticorps anti-apoc3 et leurs procédés d'utilisation
EP3746484A4 (fr) Anticorps anti-ms4a6a et leurs procédés d'utilisation
EP3394098A4 (fr) Anticorps anti-myostatine et procédés d'utilisation